Glenmark bags USFDA nod for Nintedanib Capsules

Published On 2021-06-25 05:25 GMT   |   Update On 2021-06-26 05:10 GMT
Advertisement

Mumbai: Drug maker, Glenmark Pharmaceuticals Ltd, today announced that the company has received tentative approval from the United States Food & Drug Administration (USFDA) for Nintedanib Capsules, 100 mg and 150 mg.

The product is a generic version of Ofev Capsules, 100 mg and 150 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately $1.6 billion*.

Advertisement

Glenmark's current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 44 ANDA's pending approval with the USFDA.

Read also: Glenmark bags USFDA nod for Arformoterol Tartrate Inhalation Solution

Glenmark Pharmaceuticals Ltd. is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology.



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News